Shenzhen Neptunus Bioengineering Co Ltd Net Assets
Shenzhen Neptunus Bioengineering Co Ltd net assets. Based on the latest financial reports, Shenzhen Neptunus Bioengineering Co Ltd (000078) has net assets worth CN¥2.16 Billion CNY (≈ $315.45 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥25.73 Billion ≈ $3.77 Billion USD) and total liabilities (CN¥23.58 Billion ≈ $3.45 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore 000078 year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥2.16 Billion |
| % of Total Assets | 8.38% |
| Annual Growth Rate | 13.24% |
| 5-Year Change | -70.22% |
| 10-Year Change | -62.97% |
| Growth Volatility | 138.36 |
Net Assets of Shenzhen Neptunus Bioengineering Co Ltd (1995–2025)
Net assets of Shenzhen Neptunus Bioengineering Co Ltd from 1995 to 2025. This chart illustrates how Shenzhen Neptunus Bioengineering Co Ltd's net assets have evolved over time, based on quarterly financial data. See Shenzhen Neptunus Bioengineering Co Ltd balance sheet independence to measure how much of total assets are equity-financed.
Annual Net Assets for Shenzhen Neptunus Bioengineering Co Ltd (1995–2025)
The table below shows the annual net assets of Shenzhen Neptunus Bioengineering Co Ltd from 1995 to 2025. For live market cap and overall valuation, see 000078 market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥2.18 Billion ≈ $318.49 Million |
-23.46% |
| 2024-12-31 | CN¥2.84 Billion ≈ $416.13 Million |
-32.57% |
| 2023-12-31 | CN¥4.22 Billion ≈ $617.14 Million |
-30.98% |
| 2022-12-31 | CN¥6.11 Billion ≈ $894.15 Million |
-16.39% |
| 2021-12-31 | CN¥7.31 Billion ≈ $1.07 Billion |
-2.42% |
| 2020-12-31 | CN¥7.49 Billion ≈ $1.10 Billion |
-4.60% |
| 2019-12-31 | CN¥7.85 Billion ≈ $1.15 Billion |
+9.67% |
| 2018-12-31 | CN¥7.16 Billion ≈ $1.05 Billion |
+10.64% |
| 2017-12-31 | CN¥6.47 Billion ≈ $946.76 Million |
+10.07% |
| 2016-12-31 | CN¥5.88 Billion ≈ $860.13 Million |
+174.28% |
| 2015-12-31 | CN¥2.14 Billion ≈ $313.60 Million |
+20.22% |
| 2014-12-31 | CN¥1.78 Billion ≈ $260.85 Million |
-5.58% |
| 2013-12-31 | CN¥1.89 Billion ≈ $276.27 Million |
+78.62% |
| 2012-12-31 | CN¥1.06 Billion ≈ $154.67 Million |
+8.85% |
| 2011-12-31 | CN¥971.04 Million ≈ $142.09 Million |
+7.58% |
| 2010-12-31 | CN¥902.62 Million ≈ $132.08 Million |
+30.33% |
| 2009-12-31 | CN¥692.59 Million ≈ $101.35 Million |
-11.30% |
| 2008-12-31 | CN¥780.79 Million ≈ $114.25 Million |
-13.59% |
| 2007-12-31 | CN¥903.62 Million ≈ $132.23 Million |
+4.01% |
| 2006-12-31 | CN¥868.76 Million ≈ $127.13 Million |
+7.89% |
| 2005-12-31 | CN¥805.26 Million ≈ $117.83 Million |
-44.54% |
| 2004-12-31 | CN¥1.45 Billion ≈ $212.47 Million |
+0.59% |
| 2003-12-31 | CN¥1.44 Billion ≈ $211.22 Million |
-30.04% |
| 2002-12-31 | CN¥2.06 Billion ≈ $301.91 Million |
+4.48% |
| 2001-12-31 | CN¥1.97 Billion ≈ $288.97 Million |
+727.14% |
| 2000-12-31 | CN¥238.75 Million ≈ $34.94 Million |
+16.07% |
| 1999-12-31 | CN¥205.69 Million ≈ $30.10 Million |
+16.16% |
| 1998-12-31 | CN¥177.08 Million ≈ $25.91 Million |
+207.28% |
| 1997-12-31 | CN¥57.63 Million ≈ $8.43 Million |
+2.64% |
| 1996-12-31 | CN¥56.14 Million ≈ $8.22 Million |
+7.65% |
| 1995-12-31 | CN¥52.15 Million ≈ $7.63 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Shenzhen Neptunus Bioengineering Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 348709213032.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Shenzhen Neptunus Bioengineering Co Ltd Net Assets Breakdown (December 2025)
Shenzhen Neptunus Bioengineering Co Ltd net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Other Components | CN¥4.71 Billion | 384.17% |
| Total Equity | CN¥1.23 Billion | 100.00% |
Shenzhen Neptunus Bioengineering Co Ltd Competitors by Market Cap
The table below lists competitors of Shenzhen Neptunus Bioengineering Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
E&R Engineering
TWO:8027
|
$492.89 Million |
|
Equasens S. A.
PA:EQS
|
$492.93 Million |
|
PostNL NV
AS:PNL
|
$493.01 Million |
|
Huasu Holdings Co Ltd
SHE:000509
|
$493.08 Million |
|
Park Aerospace Corp
NYSE:PKE
|
$492.76 Million |
|
YG Entertainment Inc
KQ:122870
|
$492.70 Million |
|
B&S Group SA
AS:BSGR
|
$492.44 Million |
|
Solowin Holdings Ordinary Share
NASDAQ:SWIN
|
$492.41 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Shenzhen Neptunus Bioengineering Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,795,232,448 to 1,227,113,526, a change of -568,118,922 (-31.6%).
- Net loss of 563,060,359 reduced equity.
- Dividend payments of 513,154,249 reduced retained earnings.
- Other comprehensive income decreased equity by 135,556,112.
- Other factors increased equity by 643,651,799.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-563.06 Million | -45.88% |
| Dividends Paid | CN¥513.15 Million | -41.82% |
| Other Comprehensive Income | CN¥-135.56 Million | -11.05% |
| Other Changes | CN¥643.65 Million | +52.45% |
| Total Change | CN¥- | -31.65% |
Book Value vs Market Value Analysis
This analysis compares Shenzhen Neptunus Bioengineering Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.74x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 38.16x to 2.74x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1995-12-31 | CN¥0.03 | CN¥1.28 | x |
| 1996-12-31 | CN¥0.04 | CN¥1.28 | x |
| 1997-12-31 | CN¥0.04 | CN¥1.28 | x |
| 1998-12-31 | CN¥0.11 | CN¥1.28 | x |
| 1999-12-31 | CN¥0.13 | CN¥1.28 | x |
| 2000-12-31 | CN¥0.15 | CN¥1.28 | x |
| 2001-12-31 | CN¥1.08 | CN¥1.28 | x |
| 2002-12-31 | CN¥0.77 | CN¥1.28 | x |
| 2003-12-31 | CN¥0.65 | CN¥1.28 | x |
| 2004-12-31 | CN¥0.64 | CN¥1.28 | x |
| 2005-12-31 | CN¥0.32 | CN¥1.28 | x |
| 2006-12-31 | CN¥0.46 | CN¥1.28 | x |
| 2007-12-31 | CN¥0.46 | CN¥1.28 | x |
| 2008-12-31 | CN¥0.43 | CN¥1.28 | x |
| 2009-12-31 | CN¥0.39 | CN¥1.28 | x |
| 2010-12-31 | CN¥0.45 | CN¥1.28 | x |
| 2011-12-31 | CN¥0.49 | CN¥1.28 | x |
| 2012-12-31 | CN¥0.52 | CN¥1.28 | x |
| 2013-12-31 | CN¥0.86 | CN¥1.28 | x |
| 2014-12-31 | CN¥0.79 | CN¥1.28 | x |
| 2015-12-31 | CN¥0.98 | CN¥1.28 | x |
| 2016-12-31 | CN¥2.41 | CN¥1.28 | x |
| 2017-12-31 | CN¥2.10 | CN¥1.28 | x |
| 2018-12-31 | CN¥2.25 | CN¥1.28 | x |
| 2019-12-31 | CN¥2.36 | CN¥1.28 | x |
| 2020-12-31 | CN¥2.24 | CN¥1.28 | x |
| 2021-12-31 | CN¥2.22 | CN¥1.28 | x |
| 2022-12-31 | CN¥1.78 | CN¥1.28 | x |
| 2023-12-31 | CN¥1.14 | CN¥1.28 | x |
| 2024-12-31 | CN¥0.68 | CN¥1.28 | x |
| 2025-12-31 | CN¥0.47 | CN¥1.28 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Shenzhen Neptunus Bioengineering Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -45.88%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -2.11%
- • Asset Turnover: 1.01x
- • Equity Multiplier: 21.46x
- Recent ROE (-45.88%) is below the historical average (-2.11%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1995 | 21.94% | 22.82% | 0.60x | 1.59x | CN¥6.19 Million |
| 1996 | 31.19% | 21.85% | 0.63x | 2.26x | CN¥11.55 Million |
| 1997 | 31.69% | 28.97% | 0.43x | 2.54x | CN¥12.43 Million |
| 1998 | 14.83% | 40.56% | 0.28x | 1.30x | CN¥8.52 Million |
| 1999 | 15.17% | 35.15% | 0.14x | 3.14x | CN¥10.59 Million |
| 2000 | 26.11% | 30.92% | 0.23x | 3.70x | CN¥37.96 Million |
| 2001 | 4.79% | 10.43% | 0.25x | 1.83x | CN¥-86.83 Million |
| 2002 | 2.50% | 5.09% | 0.24x | 2.03x | CN¥-126.79 Million |
| 2003 | -15.60% | -17.16% | 0.32x | 2.86x | CN¥-360.99 Million |
| 2004 | 1.58% | 0.95% | 0.62x | 2.67x | CN¥-117.57 Million |
| 2005 | -107.62% | -27.91% | 0.67x | 5.78x | CN¥-810.82 Million |
| 2006 | 5.93% | 1.58% | 0.76x | 4.92x | CN¥-29.16 Million |
| 2007 | 5.17% | 1.55% | 0.80x | 4.17x | CN¥-36.11 Million |
| 2008 | 3.46% | 1.10% | 0.80x | 3.95x | CN¥-46.02 Million |
| 2009 | 2.25% | 0.52% | 0.86x | 5.03x | CN¥-48.79 Million |
| 2010 | 6.29% | 1.17% | 0.96x | 5.59x | CN¥-27.50 Million |
| 2011 | 6.63% | 0.99% | 1.10x | 6.11x | CN¥-26.65 Million |
| 2012 | 7.00% | 0.92% | 1.09x | 6.95x | CN¥-25.27 Million |
| 2013 | 7.69% | 1.46% | 1.00x | 5.27x | CN¥-35.19 Million |
| 2014 | 1.65% | 0.24% | 1.02x | 6.70x | CN¥-120.00 Million |
| 2015 | 26.31% | 4.27% | 0.87x | 7.07x | CN¥294.29 Million |
| 2016 | 7.80% | 3.08% | 0.82x | 3.10x | CN¥-118.21 Million |
| 2017 | 11.53% | 2.55% | 0.81x | 5.59x | CN¥84.66 Million |
| 2018 | 6.93% | 1.08% | 0.93x | 6.87x | CN¥-183.61 Million |
| 2019 | 3.30% | 0.50% | 1.01x | 6.58x | CN¥-419.22 Million |
| 2020 | -4.91% | -0.72% | 1.01x | 6.76x | CN¥-876.41 Million |
| 2021 | 1.60% | 0.23% | 1.09x | 6.46x | CN¥-488.92 Million |
| 2022 | -21.89% | -2.71% | 1.04x | 7.73x | CN¥-1.50 Billion |
| 2023 | -56.28% | -4.64% | 1.13x | 10.76x | CN¥-1.99 Billion |
| 2024 | -66.48% | -3.94% | 1.05x | 16.04x | CN¥-1.37 Billion |
| 2025 | -45.88% | -2.11% | 1.01x | 21.46x | CN¥-685.77 Million |
Industry Comparison
This section compares Shenzhen Neptunus Bioengineering Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $2,260,697,344
- Average return on equity (ROE) among peers: 8.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | CN¥2.16 Billion | 21.94% | 10.94x | $492.82 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $1.56 Billion | 7.90% | 1.45x | $363.79 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $366.91 Million | 9.97% | 0.26x | $4.71 Billion |
| Livzon Pharmaceutical Group Inc (000513) | $14.91 Billion | 13.83% | 0.64x | $2.63 Billion |
| Wedge Industrial Co Ltd (000534) | $654.70 Million | 1.92% | 0.87x | $1.28 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $35.11 Million | 18.13% | 0.80x | $14.36 Billion |
| Hainan Haiyao Co Ltd (000566) | $317.39 Million | 7.74% | 0.74x | $766.98 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $268.54 Million | 1.60% | 1.47x | $273.68 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $889.22 Million | 5.34% | 2.43x | $935.44 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $1.35 Billion | 7.34% | 0.44x | $3.04 Billion |
About Shenzhen Neptunus Bioengineering Co Ltd
Shenzhen Neptunus Bioengineering Co., Ltd. engages in the research and development, manufacturing, and distribution of pharmaceuticals in China. The company also provides distribution of medical devices, and other medical supplies, as well as related value-added services. It serves medical institutions, drug retailers, and distributors. Shenzhen Neptunus Bioengineering Co., Ltd. was founded in 19… Read more